# OnCo record salivary-gland (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/salivary-gland/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "salivary-gland" ;
  schema:name "Salivary gland cancers"@en ;
  schema:alternateName "Adenoid cystic carcinoma"@en, "Mucoepidermoid carcinoma"@en, "Salivary duct carcinoma"@en, "Secretory carcinoma"@en ;
  schema:description "Salivary gland cancers are a family of over 20 rare cancers, each with its own behaviour and often its own gene fusion. Surgery and radiation treat most; drug therapy is now chosen by the specific subtype, from anti-HER2 or anti-androgen drugs to NTRK inhibitors."@en ;
  schema:url <https://onco.cc/cancers/salivary-gland/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Salivary_gland_tumour> ;
  owl:sameAs <http://www.wikidata.org/entity/Q3267772> ;
  schema:citation <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1437>, <https://doi.org/10.1016/j.esmoop.2022.100602>, <https://www.accrf.org/> ;
  onco:tag "gap-fill", "head-and-neck", "rare" ;
  onco:technologies <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/carbon-ion/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/androgen-deprivation/>, <https://onco.cc/technologies/cgp/> ;
  onco:targets <https://onco.cc/targets/her2/>, <https://onco.cc/targets/androgen-receptor/>, <https://onco.cc/targets/ntrk/>, <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/met/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/enzalutamide/>, <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/axitinib/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/bayer/>, <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/daiichi-sankyo/>, <https://onco.cc/companies/eisai/> ;
  onco:pathways <https://onco.cc/pathways/ar-signaling/>, <https://onco.cc/pathways/vegf-angiogenesis/> ;
  onco:terms <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/tumour-agnostic/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-van-herpen-esmo-open/> ;
  onco:pipeline <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/technologies/carbon-ion/>, <https://onco.cc/drugs/gotistobart/>, <https://onco.cc/drugs/rem-422/> ;
  onco:standardOfCare <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/carbon-ion/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/enzalutamide/>, <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/axitinib/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/pembrolizumab/> .